ArticleBreast cancer research : BCR2026
Herpes zoster risk among female survivors of breast cancer in Japan.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurvivors of breast cancer (BC) have a higher risk of developing herpes zoster (HZ), but it remains unclear how this risk is affected by time since BC diagnosis and treatment regimen.
methodsThis matched cohort study used a large health-insurance claims database including Japanese employees and their families. Between January 2005 and December 2019, women aged 18-74 years with and without incident BC were matched 1:4 by age and timing of database entry, in the month of BC diagnosis. This study aimed to evaluate the risk of developing HZ in female BC survivors compared with women without BC, to examine temporal variations in risk during survivorship, and to assess the impact of different BC treatments on this risk. We compared the first HZ incidence using stratified Cox regression analyses over the study period, divided by follow-up length. We then estimated HZ risk by treatment regimen using unstratified Cox regression analysis, with follow-up beginning 1 year after matching.
resultsComparing 23,169 BC survivors vs 92,801 matched women without BC (median age: 49.4 years, interquartile range: 44.7-56.0 years), the HZ incidence rate (95% confidence interval) was higher in the survivors (16.5 [15.6-17.5] vs 10.6 [10.3-11.0]/1000 person-years), with an adjusted hazard ratio (aHR) of 1.57 (1.46-1.68) over the whole period. This aHR decreased over time but remained elevated up to 10 years (0-1 year: 1.90 [1.68-2.16]; 1-2 years: 1.64 [1.42-1.89]; 2-3 years: 1.30 [1.08-1.57]; 3-10 years: 1.37 [1.20-1.56]). The aHRs were 1.15 (0.98-1.36), 1.64 (1.16-2.30), 1.23 (0.94-1.62), and 1.60 (1.30-1.97), respectively, for survivors who received no chemotherapy, anthracycline-only, taxane-only, and anthracycline-plus-taxane, compared with women without BC.
conclusionsFemale BC survivors in Japan had a higher HZ risk compared with the general age-matched female Japanese population. HZ vaccination should therefore be promoted for BC survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.